American Journal of Ophthalmology
Volume 148, Issue 5 , Pages 711-717.e2 , November 2009

Bevacizumab in Inflammatory Eye Disease

,Accepted 2 June 2009.

References 

  1. Watzke RC, Packer AJ, Folk JC, Benson WE, Burgess D, Ober RR. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98:572–584
  2. Olk RJ, Burgess DB, McCormick PA. Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome (Visual prognosis). Ophthalmology. 1984;91:1592–1602
  3. Chew EY, Crawford J. Sympathetic ophthalmia and choroidal neovascularization (Case report). Arch Ophthalmol. 1988;106:1507–1508
  4. Rothova A, Suttorp-van Schulten MS, Frits TW, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–336
  5. Brown J, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996;103:1100–1105
  6. Rothova A, Berendschot TT, Probst K, van Kooij B, Baarsma GS. Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology. 2004;111:954–959
  7. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111:2299–2306
  8. Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004;111:946–953
  9. Lim WK, Buggage RR, Nussenblatt RB. Serpiginous choroiditis. Surv Ophthalmol. 2005;50:231–244
  10. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354–362
  11. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132:794–796
  12. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293:1509–1513
  13. Martidis A, Miller DG, Ciulla TA, Danis RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther. 1999;15:425–428
  14. Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology. 2003;110:1315–1320
  15. Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol. 2003;241:899–906
  16. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester JV. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol. 2005;89:147–150
  17. Nowilaty SR, Bouhaimed M. Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2006;90:982–986
  18. Lim JI, Flaxel CJ, LaBree L. Photodynamic therapy for choroidal neovascularisation secondary to inflammatory chorioretinal disease. Ann Acad Med Singapore. 2006;35:198–202
  19. Rothova A. Medical treatment of cystoid macular edema. Ocul Immunol Inflamm. 2002;10:239–246
  20. Papadaki T, Zacharopoulos I, Iaccheri B, Fiore T, Foster CS. Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm. 2005;13:469–470
  21. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331–335
  22. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1–9
  23. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143:977–983
  24. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001;132:794–796
  25. Seth RK, Stoessel KM, Adelman RA. Choroidal neovascularization associated with West Nile virus chorioretinitis. Semin Ophthalmol. 2007;22:81–84
  26. Margolis R, Lowder CY, Sears JE, Kaiser PK. Intravitreal bevacizumab for macular edema due to occlusive vasculitis. Semin Ophthalmol. 2007;22:105–108
  27. Adan A, Navarro M, Casaroli-Marano RP, Ortiz S, Molina JJ. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol. 2007;245:1873–1875
  28. Kurup S, Lew J, Byrnes G, Yeh S, Nussenblatt R, Levy-Clarke G. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol. 2009;87:349–352
  29. Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina. 2007;27:1180–1186
  30. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol. 2008;126:941–945
  31. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114:1574–1579
  32. Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol. 2007;245:917–918
  33. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28:41–45

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00410-3

doi: 10.1016/j.ajo.2009.06.010

American Journal of Ophthalmology
Volume 148, Issue 5 , Pages 711-717.e2 , November 2009

Article Tools

* Image Usage & Resolution